

Antimicrobial Susceptibility, Aerobic Bacteria, Varies

Test ID: ZMMLS

Explanation: On the effective date, breakpoint interpretations will no longer be reported for *Burkholderia cepacia* complex isolates. Rather, epidemiological cutoff value (ECV) comments will be reported with the minimal inhibitory concentration (MIC) results, as appropriate. Agar dilution testing will continue to be performed until further guidance concerning testing and reporting of this organism group is provided by the Clinical Laboratory and Standards Institute (CLSI). The routine testing panel will now include ceftazidime, meropenem, minocycline, and trimethoprim-sulfamethoxazole. Levofloxacin will be available on request. The special instructions table online has been updated to reflect these changes and can be found here: http://www.mayocliniclabs.com/it-mmfiles/Aerobic_Gram-Negative_Bacilli_Antimicrobials.pdf.

ECV comments applied to the reports are as follows:

For wild-type isolates (i.e., isolates with MICs below the ECV): "The MIC is in the range observed in isolates WITHOUT acquired resistance. However, correlation with treatment outcome is unknown. Infectious Disease consult is suggested."

For non-wild-type isolates (i.e., isolates with MICs above the ECV): "The MIC is in the range observed in isolates WITH acquired resistance. However, correlation with treatment outcome is unknown. Infectious Disease consult is suggested."

Questions

Contact Brandon DeBoom, Laboratory Resource Coordinator at 800-533-1710.